TY  - JOUR
AU  - Cassinello, J
AU  - Arranz, J A
AU  - Piulats, J M
AU  - Sanchez, A
AU  - Perez-Valderrama, B
AU  - Mellado, B
AU  - Climent, M A
AU  - Olmos, D
AU  - Carles, J
AU  - Lazaro, M
PY  - 2017
DO  - 10.1007/s12094-017-1783-2
UR  - http://hdl.handle.net/10668/11795
T2  - Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
AB  - Androgen deprivation treatment was the only treatment available for metastatic prostate cancer until recently, with docetaxel as the only treatment with a proven survival benefit in castration-resistant prostate cancer (CRPC). Several drugs have been...
LA  - en
PB  - Springer
KW  - Abiraterone
KW  - Androgen deprivation treatment
KW  - Cabazitaxel
KW  - Castration-resistant prostate cancer
KW  - Docetaxel
KW  - Enzalutamide
KW  - Hormone-sensitive advanced prostate cancer
KW  - Radium 223
KW  - Antineoplastic Agents
KW  - Humans
KW  - Male
KW  - Prostatic Neoplasms
TI  - SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017).
TY  - research article
VL  - 20
ER  -